Abiopharma

BioElectronics develops & commercializes electrical stimulation/neuromodulation technology. Its flagship technology is wearable, non-thermal pulsed shortwave therapy (PSWT), which is used to treat and manage a variety of chronic neurological disorders such as chronic pain. The company boasts 4 FDA 510 (k) clearances for its devices, backed by safety & effectiveness data from 5 randomized, controlled clinical trials and numerous other registry trials. These clearances allow for two broad indications in the treatment of pain, for all anatomical sites: 1) postoperative pain (prescription); and 2) musculoskeletal pain (OTC). The Company holds market authorization in the European Union (CE mark) & MDSAP countries (USA, Canada & Australia). The Companys strategy is to prioritize its core capabilities of manufacturing, research and development of PSWT technology. The firms focus is in developing new indications for use/market authorizations & seeking commercial partners with strong marketing & selling expertise. This has resulted in 3 major sources of revenue: 1) US OTC sales for musculoskeletal pain via marketing partners such as KT Health, LLC & DonJoy, LLC who sell custom-branded devices into the consumer retail markets; 2) US sales for postoperative pain through a 1099 sales force, who sell RecoveryRx to medical professionals; 3) International sales via our international distributor partners. http://www.actipatch.com/pharmacy

Additional info from OTC:
BioElectronics develops & commercializes electrical stimulation/neuromodulation technology. Its flagship technology is wearable, non-thermal pulsed shortwave therapy (PSWT), which is used to treat and manage a variety of chronic neurological disorders such as chronic pain. The company boasts 4 FDA 510 (k) clearances for its devices, backed by safety & effectiveness data from 5 randomized, controlled clinical trials and numerous other registry trials. These clearances allow for two broad indications in the treatment of pain, for all anatomical sites: 1) postoperative pain (prescription); and 2) musculoskeletal pain (OTC). The Company holds market authorization in the European Union (CE mark) & MDSAP countries (USA, Canada & Australia). The Companys strategy is to prioritize its core capabilities of manufacturing, research and development of PSWT technology. The firms focus is in developing new indications for use/market authorizations & seeking commercial partners with strong marketing & selling expertise. This has resulted in 3 major sources of revenue: 1) US OTC sales for musculoskeletal pain via marketing partners such as KT Health, LLC & DonJoy, LLC who sell custom-branded devices into the consumer retail markets; 2) US sales for postoperative pain through a 1099 sales force, who sell RecoveryRx to medical professionals; 3) International sales via our international distributor partners. http://www.actipatch.com/pharmacy